Harvard Bioscience Inc Total Liabilities
Harvard Bioscience Inc total liabilities. Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has total liabilities worth $68.87 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HBIO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Harvard Bioscience Inc (1998–2025)
Total liabilities of Harvard Bioscience Inc from 1998 to 2025. This chart illustrates how Harvard Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Harvard Bioscience Inc to see how much of total assets are deployed in long-term investments.
Harvard Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Harvard Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GigCapital7 Corp. Class A Ordinary Share
NASDAQ:GIG
|
USA | $70.99 Million |
|
Viscount Mining Corp.
V:VML
|
Canada | CA$229.34K |
|
Jaba I Inversiones Inmobiliarias Socimi SA
MC:YABA
|
Spain | €11.98 Million |
|
Park Elektrik Uretim Madencilik Sanayi ve Ticaret AS
IS:PRKME
|
Turkey | TL725.06 Million |
|
DNA Biomed Solns
TA:DNA
|
Israel | ILA1.77 Million |
|
Hana Must SPAC 2
KQ:208370
|
Korea | ₩6.87 Billion |
|
Logistea A
ST:LOGI-A
|
Sweden | Skr11.09 Billion |
|
Herantis Pharma Oyj
HE:HRTIS
|
Finland | €3.36 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Harvard Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Harvard Bioscience Inc assets under control.
Liquidity & Leverage Metrics
Harvard Bioscience Inc Total Liabilities Ratios Explained
Harvard Bioscience Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Harvard Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Harvard Bioscience Inc (1998–2025)
The table below shows the annual total liabilities of Harvard Bioscience Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $66.34 Million | +4.79% |
| 2024-12-31 | $63.30 Million | -1.54% |
| 2023-12-31 | $64.29 Million | -12.10% |
| 2022-12-31 | $73.14 Million | -7.35% |
| 2021-12-31 | $78.94 Million | -0.79% |
| 2020-12-31 | $79.57 Million | -4.33% |
| 2019-12-31 | $83.18 Million | -3.16% |
| 2018-12-31 | $85.89 Million | +201.85% |
| 2017-12-31 | $28.45 Million | -20.00% |
| 2016-12-31 | $35.57 Million | -16.54% |
| 2015-12-31 | $42.62 Million | +5.37% |
| 2014-12-31 | $40.45 Million | -1.29% |
| 2013-12-31 | $40.98 Million | +39.98% |
| 2012-12-31 | $29.27 Million | -5.99% |
| 2011-12-31 | $31.14 Million | -9.88% |
| 2010-12-31 | $34.55 Million | +8.05% |
| 2009-12-31 | $31.97 Million | +119.71% |
| 2008-12-31 | $14.55 Million | -41.12% |
| 2007-12-31 | $24.72 Million | +15.79% |
| 2006-12-31 | $21.34 Million | -9.63% |
| 2005-12-31 | $23.62 Million | -33.51% |
| 2004-12-31 | $35.52 Million | +20.21% |
| 2003-12-31 | $29.55 Million | +53.89% |
| 2002-12-31 | $19.20 Million | +23.49% |
| 2001-12-31 | $15.55 Million | +140.20% |
| 2000-12-31 | $6.47 Million | -48.73% |
| 1999-12-31 | $12.63 Million | +93.00% |
| 1998-12-31 | $6.54 Million | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrop… Read more